Metis Global Partners’s Puma Biotechnology PBYI Stock Holding History

Metis Global Partners’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Hold	25,264	–	–	﹤0.01%	681
2026 Q1	$161K	Sell	25,264 -17,322	-41%	-$112K	﹤0.01%	700
2025 Q4	$253K	Sell	42,586 -13,212	-24%	-$70.2K	0.01%	677
2025 Q3	$296K	Hold	55,798	–	–	0.01%	670
2025 Q2	$191K	Buy	55,798 +13,040	+30%	+$41.6K	﹤0.01%	728
2025 Q1	$127K	Buy	42,758 +3,231	+8%	+$10.1K	﹤0.01%	769
2024 Q4	$121K	Hold	39,527	–	–	﹤0.01%	768
2024 Q3	$101K	Hold	39,527	–	–	﹤0.01%	772
2024 Q2	$129K	Hold	39,527	–	–	﹤0.01%	741
2024 Q1	$209K	Buy	+39,527	New	+$213K	0.01%	710

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metis Global Partners's PBYI Position: Q2 2026 in Review

Metis Global Partners held its Puma Biotechnology (PBYI) position steady in Q2 2026 at 25,264 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #681.

Metis Global Partners first reported a position in PBYI in Q1 2024 and has held it in 10 quarters since. The position peaked at $296K in Q3 2025. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

Metis Global Partners held 25,264 shares of Puma Biotechnology worth $205K as of Q2 2026.
Metis Global Partners left its Puma Biotechnology share count unchanged in Q2 2026.
Puma Biotechnology made up ﹤0.01% of Metis Global Partners's portfolio in Q2 2026, its #681 holding.
Metis Global Partners first reported a position in Puma Biotechnology in Q1 2024 and has held it in 10 quarters since.
Metis Global Partners's Puma Biotechnology position peaked at $296K in Q3 2025.
161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.